Speciality Coagulation
Whether you are working with coagulation factors, coagulation inhibitors, or fibrinolysis inhibitors, our extensive range of ELISA provides specific and sensitive results to monitor and quantify coagulation in various human sample matrices.
Hemophilia A
Hemophilia encompasses a group of inherited disorders that alter blood coagulation. Classical haemophilia, also known as haemophilia A, is a hereditary haemorrhagic disorder resulting from a congenital deficit of factor VIII that manifests as protracted and excessive bleeding either spontaneously or secondary to trauma.
Our KRIBIOLISA™ Factor VIII is a chromogenic assay for measuring factor VIII activity. It contains reagents from human origin and is therefore fully sensitive to the factor VIII mimetic Emicizumab (Hemlibra® by Roche) used in haemophilia A treatment.
In case a test kit insensitive to Emicizumab is required, we offer a solution with our KRIBIOLISA™ Factor VIII (bovine reagent component).
In sum, the KRIBIOLISA™ Factor VIII Chromogenic Assay kits allow measuring Emicizumab in treated haemophiliacs (kit with human FX) and evaluating anti-FVIII inhibitor titres in presence of Emicizumab (kit with bovine FX).
Our KRIBIOLISA Emicizumab ELISA (#KBI1297) is a double antibody sandwich assay using Factor IX and Factor X recombinant proteins to capture Emicizumab in human serum and plasma and a biosimilar Emicizumab as standard. The ELISA offers simplicity in testing and directly estimates Emicizumab levels in patient samples.
Hemophilia B
Haemophilia B (also known as Factor IX deficiency) is a type of clotting disorder, much rarer than Haemophilia A (Classic Haemophilia or Factor VIII deficiency).
Our chromogenic assay KRIBIOLISA™ Factor IX Chromogenic Assay and ELISA kit serves to measure factor IX activity in human citrated plasma or factor IX concentrates.
Von Willebrand Factor / ADAMTS-13
Von Willebrand factor (vWF) is glycoprotein crucial to primary hemostasis through platelet and subendothelial collagen adhesion, and the intrinsic coagulation cascade, through factor VIII stabilization.
The von Willbrand factor protects factor VIII against premature proteolytic degradation and secures its transport to where it is needed as co-factor in the course of secondary haemostasis.
For the diagnosis of von Willebrand disease, we offer GENLISA™ VWF ELISA (#KBH1140, Assay Range: 0 – 1,000 ng/ml)
Our GENLISA™ ADAMTS-13 ELISA (#KBH3484) allows determination of ADAMTS-13 antigen with the highest sensitivity.
Monitoring of Anticoagulants
- Our monitoring assays cover the entire spectrum of anticoagulants. The anticoagulants used nowadays can be divided into:
- Vitamin K antagonists such as Marcumar®
- Heparins (UFH, LMWH) and heparinoids, e.g. Danaparoid Sodium (Orgaran®) and Fondaparinux (Arixtra®)
- Direct Xa Inhibitors such as Apixaban (Eliquis®), Rivaroxaban (Xarelto®) and Edoxaban (Lixiana®)
- Direct Thrombin Inhibitors (anti-IIa) such as Argatroban (Argatra®), Dabigatran (Pradaxa®), Hirudin and Bivalirudin (Angiox®)
KRISHZYME™ Anti-Factor IIa (KBBA03) / KRISHZYME™ Anti-Factor Xa (KBBA04) Chromogenic Assay Kits
Our simple validated for specific analytes help researchers to use our Factor IIa and Factor Xa chromogenic kits. These kits are validated with NIBSC standards and where claimed against the innovator drugs to make the kits as per the specific protocol suitable for us.
Direct Oral Anticoagulants (DOACs)
In coagulation disorder therapy, the Direct Oral Anticoagulants (DOACs) Apixaban (Eliquis®), Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®) and Edoxaban (Lixiana®) have established themselves increasingly for manufacturers for the QC and end-point release of production lots.
If present in plasma samples, they interfere with a big number of coagulation assays. Our new range of kits are soon being launched to overcome this.
Fibrinolysis
Fibrinolysis is a normal body process. It prevents blood clots that occur naturally from growing and causing problems. Primary fibrinolysis refers to the normal breakdown of clots. Secondary fibrinolysis is the breakdown of blood clots due to a medical disorder, medicine, or other cause. Physiological fibrinolysis means the cleavage of fibrin by the enzyme plasmin. The fibrinolytic system, i.e. the degradation of fibrin, must be in a state of equilibrium with the coagulation system, which provides fibrin deposits.
For the determination of plasminogen activity, we offer our GENLISA™ tPA ELISA (#KBH3707, Assay Range: 0 – 10 ng/ml).
The fibrinolytic system is kept under control by inhibitors (like alpha-2-antiplasmin, PAI-1). For investigating these inhibitors, our following test kits are suited:
GENLISA™ Alpha-2-Antiplasmin ELISA (#KBH0423, Assay Range: 0 – 300 ng/ml)
GENLISA™ PAI-1 ELISA (#KB1099, Assay Range: 0 -800 pg/ml)
Heparin Induced Thrombocytopenia (HIT-II)
Heparin-Induced Thrombocytopenia (Type II) is a rare and dangerous condition which occurs in 1% to 3% of patients receiving heparin. Thrombocytopenia occurs 5 to 10 days after heparin therapy decreasing the platelet counts by 30 to 50%. Type II HIT primarily affects the venous system but arterial involvement is not uncommon.
GENLISA™ PF4 ELISA specifically detects Platelet Factor 4 in serum and platelet poor plasma. HIT is caused by development of IgG antibodies to heparin-platelet factor 4 (PF4) complexes. This kit helps in estimation of Platelet Factor 4 (#KBH1108 Assay Range: 0 – 100 pg/ml) and helps researchers look at the HIT-II phenomenon in patients.
Other Coagulation Factors
Coagulation Related ELISA available for Other Species: